Prostate cancer clinical stage does not predict recurrence

	Tweet

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer’s clinical stage and a patient’s risk of cancer recurrence after having his prostate removed.

One of the primary purposes of staging prostate cancers is to help physicians determine a patient’s prognosis. For example, a more advanced clinical stage should indicate a higher risk of cancer recurrence after treatment. Surprisingly, however, researchers have found that clinical stage is of questionable utility for predicting disease recurrence after surgical removal of the prostate (radical prostatectomy) in patients with localized prostate cancer.

Adam Reese, MD, of the University of California, San Francisco, and his colleagues questioned whether staging errors are responsible for this discrepancy. In other words, do physicians often inaccurately stage prostate cancer cases, and if so, does this account for the inconsistent reliability of clinical staging for predicting prostate cancer outcomes?

The investigators found that clinical stage was assigned incorrectly in 35.4 percent of 3,875 men in a multi-institutional national disease registry. The majority of these staging errors occurred because physicians frequently disregarded the results of transrectal ultrasound tests and incorrectly incorporated biopsy results when assigning stage.

Even after correcting these staging errors, however, there was no association between clinical stage and prostate cancer recurrence after radical prostatectomy. “Our findings question the utility of our current staging system for localized prostate cancer,” said Dr. Reese.

###

Contact: Jennifer Beal

44-012-437-70633
Wiley-Blackwell

RELATED STORIES:
Calcium consumption may cause prostate cancer in Chinese   Mediterranean Diet May Help Prevent Prostate Cancer   Low-income men show more high-risk prostate tumors   USC Leads International Program Aimed At Identifying Prostate Cancer Risk   Fatherhood linked to prostate cancer risk   Common painkillers lower levels of prostate cancer biomarker   Genetic factors implicated in survival gap for breast, ovarian or prostate cancer   A Better Blood Test for Prostate Cancer   Combination therapy improves survival for certain prostate cancer patients   New research model of human prostate cancer shows cancer development   Being active may ward off prostate cancer death   ARRA Funds Research to Improve Prostate Cancer Identification   Vitamin E, Selenium and Soy in Combination Does Not Prevent Prostate Cancer   PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients   Dutasteride useful for enlarged prostate   Testosterone Replacement in Older Men Does Not Increase Risk of Prostate Cancer   Vitamin D protects cells from stress that can lead to cancer   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   Gene Fusion Discovery May Lead to Improved Prostate Cancer Test   Don’t Give Up on Prostate Cancer Screening Just Yet   Few Side Effects from Radiation Treatment Given After Prostate Cancer Surgery   Prediction models help determine likelihood of erectile function after treatment for prostate cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]